KLAS
4.6.2024 11:01:28 CEST | Business Wire | Press release
Klas, a global leader in rugged edge technology solutions, is proud to unveil its most advanced vehicle data logging solution yet - the TRX D16. This cutting-edge device combines high-performance computing (HPC) and storage into a single platform, revolutionizing ADAS/AD development and data logging for both lab and in-vehicle use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604506618/en/
TRX D16 from Klas - HPC ADAS/AD Development Server & Cloud Scale Data Logging (Photo: Business Wire)
The TRX D16 introduces transformational advancements to in-vehicle computing and logging and unleashes technology confined to the cloud or extremely large loggers up to this point. Now, high-end computing and logging can be fitted to any vehicle platform, allowing engineers to continue pushing the limits of ADAS/AD.
With TRX D16, automotive engineers gain a high-performance and customizable platform to accommodate the evolving vehicle sensor stack and support compute-intensive software development of AI/ML training, inference, and simulation. Furthermore, the platform delivers 200Gbps of sustained logging speeds and 480TB of data storage to capture data from high-speed ethernet-based cameras, with support for denser radar and lidar point cloud captures.
Designed rugged, the TRX D16 is equally at home in the lab and the vehicle. Engineers can transfer the entire development environment workbench to the vehicle for continued development and integration of new functionality with real-world drive test scenarios.
“As a single platform, the multi-purpose TRX D16 minimizes the number of disparate systems in the vehicle and reduces the effort of moving from the lab to the vehicle,” said Frank Murray, CTO of Klas. “By reducing the time spent preparing the vehicle, engineers can focus on productive tasks of real-world validation, which includes high-performance computing for AI testing. At a program level, the result is the improved time to market for new ADAS/AD functionality.”
TRX D16 key features
The TRX D16 is designed rugged to the highest specifications of MIL-STD-461 and 810G/H to withstand the extremes of temperature, vibration and shock.
- High performance computing: AMD EPYC™ 7713P (64 core) processor and up to 768GB of RAM, designed for embedded and harsh environments in vehicles.
- Open GPU options: Numerous GPU PCIe card options are supported, allowing for more flexible and cost-effective AI/ML development environments.
- Hot-swappable storage: 480 TB storage (16x SSDs) split over two removable cassettes allows test vehicles to return to the road in minutes with minimal IT effort.
- High disk write speeds: SAS4 SED drives, plus integrated RAID for secure data capture from an increased number of high-bandwidth sensors.
- High speed connectivity: 2x 100GbE interfaces to transfer valuable data to engineering HIL/SIL workbenches.
- Flexible expansion: 2x PCIe (Gen 4) interfaces for custom I/O - automotive Ethernet, FPGA based SmartNICs, GMSL/FPD-Link/GVIF based cameras, or storage.
To learn more about the TRX D16 HPC server and vehicle data logger or Klas, visit -
https://www.klasgroup.com/markets/automotive/l4-l5-data-logging/
About Klas
Klas is an engineering and design company with over 30 years of experience developing innovative rugged communications solutions for the network edge. The company specializes in integrating enterprise networking capabilities from global IT leaders with purpose-built hardware and software platforms designed to meet market demands and the most stringent environmental requirements. Klas collaborates with strategic partners, including Cisco, Dell, and Microsoft, to support edge deployments in Government, Transportation, and Automotive industries. For more information, visit www.klasgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604506618/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom